Compare Abeona Therapeutics Inc (ABEO) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Redwire Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Redwire Corporation trades at $10.48 (market cap $2.03B). The key difference: Redwire Corporation is far larger — about 5.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | RDW | |
|---|---|---|
Market Cap | $373.32M | $2.03B |
Sector | Health | Technology |
52-Week High | $7.23 | $25.90 |
52-Week Low | $4.17 | $5.06 |
Enterprise Value | $228.22M | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
RDW trades at $11.36, up 0.44% on the day, amid a bearish technical trend and weak fundamentals. The company reported a net loss of $226.55M in 2025 with a -80.9% net income margin, though revenue grew to $335.38M. Recent news highlights volatility driven by SpaceX's IPO impact and a new defense contract, while analyst consensus remains bullish with an $19.00 price target.
The outlook is challenged by persistent losses and cash burn, but strong analyst buy ratings and contract wins offer potential upside. Key risks include dilution from equity offerings, intense space sector competition, and reliance on financing to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
